Godrej Agrovet Q2 FY27 Revenue up 17% to ₹2,995 Cr; PAT grows 22%
Godrej Agrovet reported Q2 FY27 revenue of ₹2,995 crore, up 17% YoY, with PAT at ₹103 crore, up 22%. For H1 FY27, revenue was ₹5,847 crore (up 13%) and PAT was ₹229 crore (down 2%). Animal Nutrition revenue grew 14% and Oil Palm revenue rose 28%. Crop Care revenue increased 42%.
The announcement provides detailed financial results for the quarter and half-year, including revenue, EBITDA, PBT, and PAT, along with segment-wise performance. This information is crucial for investors to assess the company's financial health and strategic progress.
The company reported positive year-on-year growth in revenue and PAT for the quarter, along with strong performance in key segments like Animal Nutrition and Oil Palm, indicating a positive outlook despite challenging market conditions.
Godrej Agrovet Limited announced its Standalone and Consolidated Unaudited Financial Results for the Quarter and Half Year ended September 30, 2026. The company reported a 17% year-on-year revenue growth for the second quarter of FY27, reaching ₹2,995 crore. Profit After Tax (PAT) saw a 22% increase to ₹103 crore.
For the half-year ended September 30, 2026, revenue grew by 13% to ₹5,847 crore, while PAT declined by 2% to ₹229 crore. EBITDA remained flat at ₹222 crore for Q2 FY27, with a margin contraction of 120 bps due to input cost inflation. Profit Before Tax (PBT) grew 5% to ₹131 crore in Q2 FY27.
The company's Animal Nutrition segment showed strong performance with revenue growth of 14% and EBIT growth of 32%, driven by higher realizations and volumes. The Oil Palm business reported a robust 28% revenue growth, supported by better realizations. The Crop Care segment experienced a 42% revenue growth, largely due to the ramp-up of Ashitaka®, but profitability was impacted by El Niño. Astec Lifesciences' revenue declined by 3% due to weak demand. Creamline Dairy's revenue grew by 6%, driven by pricing and value-added product salience, though margins were impacted by milk inflation. Godrej Foods reported an 8% revenue increase, with strong B2C growth.
Godrej Agrovet highlighted its strategic shifts, including product premiumization in Animal Nutrition, expansion in Oil Palm, and product innovation in Crop Care. The company also emphasized its ESG initiatives, focusing on renewable energy, GHG emission reduction, and sustainable practices.
What to do with a filing like this
Godrej Agrovet Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Godrej Agrovet Limited. Read the original for the full detail.